Tom Yates is an NIHR Academic Clinical Fellow and a specialist registrar in infectious diseases and general medicine.
He holds a BSc in Immunology and Cellular Pathology (UCL, 2006), an MSc in Epidemiology (LSHTM, 2012), a Diploma in HIV Management (College of Family Physicians of South Africa, 2014) and a PhD in Epidemiology (UCL, 2016).
Prior to joining Imperial College, Tom was a Visiting Scientist at the KEMRI-Wellcome Trust Research Programme in Kilifi (2016), a Visiting Researcher at the Africa Centre (now part of AHRI) in KwaZulu-Natal (2013-14), and an Honorary Clinical Research Fellow at Oxford Vaccine Group (2010-11).
Tom's research has focused on the epidemiology and control of Mycobacterium tuberculosis in high burden settings (particularly South Africa). Other interests include CMV, randomised controlled trials, Mendelian randomisation and the barriers migrant communities face in accessing NHS services.
He set up and is an active member of North London TB Journal Club. He is an investigator on Umoya omuhle, a collaborative research project investigating nosocomial transmission of Mycobacterium tuberculosis in clinics in South Africa. Tom is currently participating in the NIHR Associate PI scheme for the RECOVERY trial.
Current funders: NIHR, the UK Medical Research Council, ESRC (via GCRF), and the Colt Foundation. Also supported, in part, by the BRC of Imperial College Healthcare NHS Trust.
et al., 2021, Estimating the contribution of transmission in primary healthcare clinics to community-wide TB disease incidence, and the impact of infection prevention and control interventions, in KwaZulu-Natal, South Africa
et al., 2021, Modelling the effect of infection prevention and control measures on rate of Mycobacterium tuberculosis transmission to clinic attendees in primary health clinics in South Africa
et al., 2021, Waiting times, patient flow, and occupancy density in South African primary health care clinics: implications for infection prevention and control
et al., 2021, Estimating ventilation rates in rooms with varying occupancy levels: Relevance for reducing transmission risk of airborne pathogens, Plos One, Vol:16, ISSN:1932-6203
et al., 2021, An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot study, Bmc Infectious Diseases, Vol:21, ISSN:1471-2334